Duke Clinical Research Institute, Durham, NC, USA.
Monash Cardiovascular Research Centre, Monash University, 246 Clayton Road, Clayton, VIC, 3168, Australia.
Am J Cardiovasc Drugs. 2020 Feb;20(1):11-18. doi: 10.1007/s40256-019-00363-3.
Despite the widespread use of statins in the setting of high cardiovascular risk, many patients continue to experience clinical events. This highlights the need to identify additional therapeutic strategies for high-risk patients. Interest in the use of omega-3 polyunsaturated fatty acids to prevent cardiovascular disease has been high for several decades. Despite promising results from before the statin era, many clinical trials have produced disappointing findings regarding products containing conventional doses of omega-3 fatty acids. More recent clinical trials using high doses of omega-3 fatty acids in targeted populations have suggested potential benefit when targeting the risk driven by atherogenic dyslipidemia. We review the clinical implications of completed and ongoing trials.
尽管在心血管风险较高的情况下广泛使用了他汀类药物,但许多患者仍继续经历临床事件。这突出表明需要为高风险患者确定其他治疗策略。几十年来,人们一直对使用ω-3 多不饱和脂肪酸预防心血管疾病很感兴趣。尽管在他汀类药物时代之前的研究结果令人鼓舞,但许多临床试验在使用常规剂量ω-3 脂肪酸的产品方面得出了令人失望的结果。最近在目标人群中使用高剂量ω-3 脂肪酸的临床试验表明,针对动脉粥样硬化性血脂异常驱动的风险可能具有潜在益处。我们回顾了已完成和正在进行的试验的临床意义。